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Reversible Cerebral Vasoconstriction Syndrome in Patients with
Coronavirus Disease: A Multicenter Case Series
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Background and objectives: RCVS (Reversible Cerebral Vasoconstrictive Syndrome) is
a condition associated with vasoactive agents that alter endothelial function. There
is growing evidence that endothelial inﬂammation contributes to cerebrovascular
disease in patients with coronavirus disease 2019 (COVID-19). In our study, we
describe the clinical features, risk factors, and outcomes of RCVS in a multicenter
case series of patients with COVID-19. Materials and methods: Multicenter retrospective case series. We collected clinical characteristics, imaging, and outcomes of
patients with RCVS and COVID-19 identiﬁed at each participating site. Results: Ten
patients were identiﬁed, 7 women, ages 21 62 years. Risk factors included use of
vasoconstrictive agents in 7 and history of migraine in 2. Presenting symptoms
included thunderclap headache in 5 patients with recurrent headaches in 4. Eight
were hypertensive on arrival to the hospital. Symptoms of COVID-19 included
fever in 2, respiratory symptoms in 8, and gastrointestinal symptoms in 1. One
patient did not have systemic COVID-19 symptoms. MRI showed subarachnoid
hemorrhage in 3 cases, intraparenchymal hemorrhage in 2, acute ischemic stroke in
4, FLAIR hyperintensities in 2, and no abnormalities in 1 case. Neurovascular imaging showed focal segment irregularity and narrowing concerning for vasospasm of
the left MCA in 4 cases and diffuse, multifocal narrowing of the intracranial vasculature in 6 cases. Outcomes varied, with 2 deaths, 2 remaining in the ICU, and 6
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surviving to discharge with modiﬁed Rankin scale (mRS) scores of 0 (n=3), 2 (n=2),
and 3 (n=1). Conclusions: Our series suggests that patients with COVID-19 may be at
risk for RCVS, particularly in the setting of additional risk factors such as exposure to
vasoactive agents. There was variability in the symptoms and severity of COVID-19,
clinical characteristics, abnormalities on imaging, and mRS scores. However, a larger
study is needed to validate a causal relationship between RCVS and COVID-19.
Key Words: RCVS—COVID-19—SARS-CoV-2—Stroke
© 2021 Published by Elsevier Inc.

Introduction
The reversible cerebral vasoconstriction syndrome
(RCVS) is characterized by severe thunderclap headache
with angiography showing diffuse, multifocal, segmental constriction of cerebral arteries which typically
resolves within 3 months. The headache may or may not
be accompanied by focal deﬁcits that result from ischemic stroke, convexal subarachnoid hemorrhage, intraparenchymal hemorrhage, or reversible cerebral edema.
It is typically provoked by vasoconstrictive agents, triggered by sexual activity or valsalva maneuvers, and
associated with conditions such as pregnancy or postpartum state, catecholamine-secreting tumors, and intracranial vascular lesions.1
Cerebrovascular complications occur in 0.5 to 5% of
acute COVID-19 infections.2-5 Acute ischemic stroke comprises the majority of cases, but intracerebral hemorrhage,6 cerebral venous sinus thrombosis,7,8 the posterior
reversible encephalopathy syndrome (PRES)9 and two
cases of RCVS14,15 have also been reported. There are several mechanisms by which COVID-19 infection may lead
to stroke, including exacerbation of pre-existing underlying vascular risk factors, viral mediated hypercoagulability, hyperinﬂammatory state, general critical illness,
hypoxia, hypotension, direct cardiac effects, but also via
activation of the renin-angiotensin system, and direct
endothelial invasion leading to endotheliitis.10-13 In the
latter two mechanisms, cellular invasion by the SARSCoV-2 virus occurs via binding of the viral spike protein
to the ACE2 receptor which leads to the downstream
effects of vasoconstriction, hypercoagulability, a proinﬂammatory state, sympathetic hyperactivity and subsequent blood pressure elevation and cerebral autoregulation failure.10,11 The pathophysiology of RCVS remains
unknown but could be plausibly related to SARS-CoV-2
infection given its proposed mechanisms of endothelial
dysfunction, dysregulation of cerebral arterial tone, and
sympathetic hyperactivity that are thought to provoke
cerebral vasoconstriction.1,16 This is based on its natural
history, lack of histological ﬁndings on brain biopsy, signiﬁcant overlap with PRES, and its association with sympathomimetic vasoactive substances and catecholamine
secreting tumors.17 To investigate the relationship further,
we present a multicenter case series of ten patients with
concomitant RCVS and acute COVID-19 infection.

Materials and methods
This study was approved or exempted by the institutional review boards of Boston Medical Center, PrismaHealth, University of Mississippi, University of Florida,
University of Toledo, Stanford University, and Henry
Ford Hospital.

Results
Patient characteristics
The patients ranged from 21 to 62 years in age. Seven of
ten of the patients were female. 6 patients were Caucasian,
3 were African American, and 1 was Haitian Creole. Common comorbidities included hypertension in ﬁve patients,
diabetes mellitus in three patients, hyperlipidemia in four
patients, obesity in four patients, and obstructive sleep
apnea in one patient. Further details of the patient characteristics are described in Table 1.

Features of COVID-19
Nine patients were diagnosed with COVID-19 within
30 days prior to the RCVS diagnosis, one patient was
diagnosed more than 30 days prior to the RCVS diagnosis,
and one patient was diagnosed in the 30 days following
RCVS diagnosis. Nine patients experienced systemic
symptoms of COVID within 30 days prior to RCVS diagnosis and one patient was asymptomatic. The patient
who was diagnosed with COVID-19 more than 30 days
prior to RCVS diagnosis was ﬁrst admitted less than
45 days prior for COVID Pneumonia, had improved respiratory status for discharge, then worsened and required
readmission during which RCVS was diagnosed. The last
patient was admitted with RCVS and then had a positive
COVID PCR test two weeks later. Her symptoms were
mild cough and sore throat which became noticeable to
her within 48 hours after her RCVS presentation. Because
her symptoms were so mild, the temporal course was
unclear and she eventually reported her symptoms as an
outpatient two weeks later when the cough and sore
throat were persistent. Further details of the temporal
relationship of COVID symptoms to RCVS diagnosis are
detailed in Table 1. COVID-19 was identiﬁed from nasopharyngeal or respiratory specimens with positive

Variables

Patient 1

Patient 2

Patient 3

Age (years), sex
Ethnicity

62, Female
Caucasian

39, Female
Caucasian

Presenting
symptoms upon
admission

Hyperactive
delirium

RCVS symptoms

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

47, Female
55, Male
African American Caucasian

35, Male
Caucasian

54, Female
Caucasian

54, Female
Haitain Creole

25, Female
Caucasian

Thunderclap
headache,
confusion

Hypoxia,
Weakness, diffiencephalopathy
culty speaking

Thunderclap
Thunderclap
headache
headache
(recurrent, 2 days (recurrent, 2
between
weeks between
episodes)
episodes)

37, Female
African
American
Thunderclap
headache
(recurrent)

New posterior
headache,
hyperactive
delirium

Thunderclap
headache

Obtundation

Broca’s aphasia, Thunderclap
right hemiparesis, headache
left arm
(recurrent, 3
hemiparesis
episodes)

21, Male
African
American
Obtundation, acute
cardiogenic
shock, HFrEF
10%, acute liver/
pancreas/renal/
respiratory
failure)
Obtundation

Focal Neurologic
Deficits?

No

Yes R hemiparesis

No

NIHSS
Initial Blood
Pressure
Stroke/CV Risk
Factors

20
145/64

12
144/73

27
270/-

Yes Right
No
hemiparesis,
Broca’s aphasia,
Left arm
weakness
20
0
119/59
149/78

HTN, Type II
HTN, Type II
DM, OSA,
DM, HLD,
Migraine,
Obesity
Obesity (BMI 37) (BMI 49)
Bupropion,
Medication or Drug Duloxetine,
Citalopram
Fluoxetine
exposure known to
be associated with
RCVS

Medication or drug
exposure
discontinued?

Patient 4

Encephalopathy,
dyspnea

Thunderclap
Headache
(recurrent)

Thunderclap
headache
(recurrent, 2
weeks between
episodes)
No

Encephalopathy,
aphasia, right
hemiplegia

Yes global
No
aphasia, right
hemianopsia,
right hemiplegia

No

No

0
148/88

27
218/123

0
140/65

2
138/92

12
80/50

HLD

HTN, HLD

Tobacco use

HTN, Obesity None

Thunderclap
Thunderclap
headache (recur- headache
rent, 3 episodes) (recurrent)

HTN, DM, HLD,
Obesity,
Migraine

None

None

Citalopram

OTC nasal
decongestants

Escitalopram,
Marijuana
Lurasidone, Barbiturates, Opiates

None

Discontinued

N/A

No

Discontinued

Discontinued

Discontinued

Discontinued

?Supplements:
Citalopram,
None
Red rice yeast,
Cetrizine,
milk thistle, fish
Denosumab,
oil, turmeric?
Oxcarbazepine,
Rosuvastatin,
Tamoxifen, Ibuprofen, Excedrin
Discontinued
Discontinued
N/A

No

No

No

N/A

N/A

No

No

Instructed to
stop marijuana use
No
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Table 1. Characteristics and outcomes of patients with reversible cerebral vasoconstriction syndrome and coronavirus disease 2019.

No

(Continued)
3

4

Table 1 (Continued)
Variables
Pregnant or
postpartum?
RCVS2 Score
Method and timing
of testing for
COVID-19
COVID-19
Symptoms

Timing of COVID
symptoms to RCVS
diagnosis
Nadir O2 saturation/
PaO2/O2
requirements
Requiring ICU level
care for COVID-19
related respiratory
complications?
Use of IA CCB or
Vasodilators

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

4
PCR positive <
30 days prior

10
PCR positive <
30 days prior

3
PCR positive <
30 days prior

3
PCR positive <
30 days prior

5
PCR positive <
30 days prior

Dyspnea on
Asymptomatic
exertion, hypoxia- malaise,
arthralgias, posterior headache,
poor appetite,
diarrhea, generalized weakness

Hypoxia,
dyspnea, fever

Severe dyspnea
and hypoxia
(severe ARDS)
requiring
intubation

Dyspnea

10
1
PCR positive <
Positive test <
30 days of RCVS 30 days prior
diagnosis
Mild cough, sore Cough,
throat
diaphoresis

25 days prior

Asymptomatic

21 days prior

21 days prior

13 days prior

82%

90%

78% at
100% FIO2

PF ratio: 80

No supplemental No supplemental 94% on 5L
O2 requirement
O2 requirement

No supplemental O2 requirement

Ventilated, now
extubated

Yes

No, for SAH/
vasculopathy

Yes

Yes

No

No

Yes

No

No

Yes

No

No

No

No

No

No

No

Yes IA
nicardipine

No

IV dexamethasone No

No

No

Yes PO
nimodipine, IA
verapamil, IA
milrinone
IV

Currently
admitted,
remained
intubated on
ventilator

>30 days prior

Patient 8

Patient 9

9
PCR positive
< 30 days
prior
Fever, myalgia,
Headache,
cough, headache Anosmia,
Agnosia

Patient 10

9
Positive test <
30 days prior

0
PCR Positive
>30 days prior

21 days prior

Severe dyspnea and
hypoxia (severe
ARDS) complicated by second
admission with
multi organ system failure and
encephalopathy
requiring
intubation
>30 days prior

Discharged home; Discharged home; Discharged to acute Deceased
mRS 0
mRS 0
rehab; mRS 3

2 days prior

Currently admitted,
Discharged
home with
extubated in ICU,
vision rehab; to be downgraded
soon
mRS 2

K. ARANDELA ET AL.

Use of
IV dexamethasone No
PO prednisone
corticosteroids
methylprednisolone No
IV dexamethasone
Outcomes at time
Discharged to
Discharged home Deceased
of submission
acute rehab;
with home
mRS 0
health. mRS 2

Within 48 hours
after RCVS Dx

Patient 7
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Table 2. Laboratory values in patients with reversible cerebral vasoconstriction syndrome and coronavirus disease 2019.
Laboratory
Variables
(Highest
Recorded
Value)

Patient 1 Patient 2 Patient 3 Patient 4 Patient 5

Patient 6 Patient 7 Patient 8 Patient 9

Patient 10

WBC
Neutrophils
Lymphocyte/
Absolute
Lymphocyte
Count
Platelet Count
PT
PTT
Fibrinogen
D-Dimer

6.7
13.6
58.70% 60
34

22.1
15.32
0.66

12.4
11.6
94.40% 3%
-

9.6
9.8
77.60% 74
14.90% 3.4

18.4
80
17

6.17
4.61
1.19

2.0
78%
7%

264
14.4
38
276
2.84

121
15
22
-

148
599
73225

294
10.8
36
-

135
1.1
-

455
13.2
33
703
3354

369
13.7
34
153

242
10
24.6
369
0.23

Ferritin
CRP
ESR
CK
LDH
Procalcitonin
Lumbar
Puncture

168
133
48
469
0.29
No

14.7
119
No

230
33.9
>120
1.84
No

171
15.5
32
>20.00
(upper
cutoff)
2414
287
n/a
69
555
1.4
No

9
Yes,
unremarkable

14
No

490
87.6
44
37
386
0.12
No

32.3
>130
156
0.06
No

155.1
0.36
Yes,
unremarkable

40k
120
>500
(upper
cutoff)
No

polymerase chain reaction testing in eight of ten patients.
The remaining two testing methods could not be conﬁrmed.
Typical systemic symptoms of COVID-19 included
fever in two, cough/respiratory symptoms in eight, GI
symptoms in one, headache with anosmia in one, and one
was asymptomatic. With regards to severity, four patients
required ICU admission for COVID-19 related respiratory
complications while the remaining patients were managed on the medical ﬂoor. COVID-related hypercoagulability labs (Table 2) showed D-dimer values elevated in
seven patients (0.23 to 73,225 ng/mL). CRP values were
obtained and elevated in six patients (14.70 to 133 mg/L).

RCVS risk factors and onset
Five out of ten patients were regularly using medications previously associated with RCVS; 5 were taking
Selective Serotonin Reuptake Inhibitors and 1 was taking
nasal decongestants. One patient took red rice yeast, milk
thistle, ﬁsh oil, and turmeric. The last three patients did
not take any medications. Eight out of ten patients had
negative urine drug screens. Two cases were associated
with illicit drugs with one patient using barbiturates and
opiates, and another patient with daily marijuana use. Of
seven female patients, ﬁve had negative hCG pregnancy
tests and none were within the post-partum period. Only
two out of ten patients had a condition associated with
RCVS (migraine).

Features of RCVS
Five patients experienced at least one thunderclap
headache with 4 patients experiencing recurrent thunderclap headaches. Triggering factors for headache identiﬁed
were orgasm, Valsalva maneuver while straining, and a
root canal. Associated neurologic deﬁcits included
encephalopathy in four, hemiparesis in two, aphasia in
two, and visual deﬁcits in two. Eight patients were hypertensive on arrival with blood pressure ranging from 140/
65 to greater than 270 systolic. One patient was normotensive upon hospital arrival and the remaining patient was
in septic shock requiring vasopressor support.

RCVS brain and neurovascular imaging
MRI Brain identiﬁed acute ischemic strokes in 4 cases,
FLAIR hyperintensities in 2, subarachnoid hemorrhage in
3, and intraparenchymal hemorrhage in 2. One patient
did not have acute ﬁndings on an MRI Brain with contrast. One patient had a CT without subarachnoid hemorrhage or stroke. Only two patients had delayed interval
imaging and in one case the repeat MRI Brain at 3 months
showed resolution of the FLAIR hyperintensities involving the bilateral parietal and occipital lobes while an
MRA showed resolution of previously seen multivessel
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narrowing and irregularity. In the other case, the repeat
CTA Head/Neck at 3 months showed signiﬁcant
improvement in the previously seen multivessel stenosis.
Ten patients underwent neurovascular imaging with
most patients receiving a combination of CTA (n=9),
MRA (n=5), and conventional angiogram (n=6). Four
patients had focal segment irregularity and narrowing
concerning for vasospasm. All four patients had focal
involvement of the left middle cerebral artery. Six patients
had diffuse, multifocal narrowing of the intracranial vasculature. One patient had only distal branch involvement
while two patients had both proximal and distal focal
involvement of the left middle cerebral artery. Further
details of the brain and neurovascular imaging are
described in Table 3 and depicted in Figs. 1 3.

RCVS treatments and outcomes
Only two patients were administered IA calcium channel blockers. One patient was administered verapamil
and milrinone during her cerebral angiogram with moderate improvement of her diffuse, intracranial vasospasm.
One patient was administered daily intra-arterial nicardipine. Five patients were administered corticosteroids,
three were given IV dexamethasone, one was given IV
methylprednisolone, and one was given PO prednisone.
Two patients remain hospitalized in the ICU. Two
patients died during hospitalization. The remaining
patients were discharged: two to an acute rehabilitation
center and four were discharged home. The patients who
were discharged from the hospital had modiﬁed Rankin
scale (mRS) scores of 0 (n=3), 2 (n=2), and 3 (n=1).

Discussion
In our case series, we identiﬁed 10 patients who developed RCVS in the setting of COVID-19 infection. Of these
cases, 3 patients did not have a provoking condition or
medication, suggesting there may be an independent
association between RCVS and COVID-19 infection.
Although RCVS has not been historically associated with
infections, there are several reasons to suspect that
COVID-19 infection may speciﬁcally contribute to
increased risk for development of RCVS.
Cellular invasion by the SARS-CoV-2 virus occurs via
binding of the viral spike protein to the ACE2 receptor
with downstream effects on the renin-angiotensin system
leading to vasoconstriction, a hypercoagulable, proinﬂammatory state, sympathetic hyperactivity leading to
elevations in blood pressure, and cerebral autoregulation
failure.10,11 In many ways this mirrors the proposed pathophysiology in RCVS, where endothelial dysfunction,
dysregulation of cerebral arterial tone, and sympathetic
hyperactivity are thought to provoke cerebral
vasoconstriction.1,16 In our series, 7 patients were hypertensive on arrival; ﬁve had mild hypertension and two
had hypertensive crises. This observation suggests that

dysfunction of cerebral autoregulation from COVID-19
may manifest with hypertension as one of the clinical
characteristics in RCVS.
Tissue expression of ACE2 receptors determines viral
tropism. The ACE2 receptors are expressed on a myriad
of tissues outside of the respiratory tract including endothelial cells within the cerebrovasculature which may contribute to pathogenesis of stroke.18 Indeed SARS-CoV-2
endotheliitis has been described radiographically and via
pathology causing strokes.12,13 This same mechanism
could putatively lead to other conditions of endothelial
dysfunction within the cerebrovasculature leading to
PRES or RCVS.
It is possible that systemic critical illness, and a hyperinﬂammatory state in COVID-19 may directly contribute to
the development of RCVS. The SARS-CoV-2 virus has
been implicated in cytokine and interleukin-6 mediated
inﬂammation of the intracranial vasculature.18,19 Interleukin-6 has been detected in higher levels in those patients
meeting WHO criteria for severe COVID-19 Pneumonia.20
For this reason, tocilizumab (an IL-6 inhibitor) has been
utilized as a treatment in COVID. Yet the use of tocilizumab itself has also been associated with development of
PRES in COVID.9 In our series, two patients were diagnosed with COVID-19 ARDS and three additional
patients required ICU level of care. Neurovascular imaging was obtained in these patients and showed multifocal
paucity of opaciﬁed intracranial vessels concerning for
vasospasm. This observation suggests that there may be
an association between the severity of the hyperinﬂammatory state and respiratory symptoms of COVID-19 with
RCVS-related diffuse, intracranial vasospasm. It is also
quite possible that RCVS is occurring in many other
patients with severe COVID-19 but is not detected due to
critical illness or poor prognosis limiting neurologic evaluation and diagnostics including angiography.
Brain parenchymal imaging in RCVS has been reported
as normal in 21-55% of patients at symptom onset, but
this varies from study to study. Common ﬁndings on
imaging include: convexity non-aneurysmal subarachnoid hemorrhage in 22-34%, intracerebral hemorrhage in
6-20%, watershed ischemic stroke in 29%, and reversible
vasogenic edema in 38%.21,22 Of our cohort of 10 patients,
two patients had brain parenchymal imaging without
acute ﬁndings. MRI identiﬁed subarachnoid hemorrhage
in 3 cases, intraparenchymal hemorrhage in 2, acute ischemic strokes in 4, and FLAIR hyperintensities in 2. The distribution of lesions in our cohort are similar to that
reported in other studies. However it is notable that while
ischemic strokes in RCVS have been mainly reported in
arterial watershed regions, in our cohort, 4 had strokes
which were far more extensive. This suggests ischemia in
COVID-related RCVS may be more profound. Whether
this is due to more severe vasospasm or perhaps due to
host factors in the setting of critical illness with COVID-19
infection such as hypotension, hypoxemia, hypercapnia,
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Table 3. Imaging findings in patients with reversible cerebral vasoconstriction syndrome and coronavirus disease 2019.
Patient

Imaging

Patient 1

MRI: Hyperintense T2 and T2 FLAIR signal in the frontal, temporal, parietal, and occipital subcortical white matter
and pons without restricted diffusion or enhancement.
MRA: Long segment irregularity and narrowing of distal left MCA) with most pronounced involvement of the
ACA and left MCA branches. Long segment irregularity and narrowing of distal right PCA branches with lesser
involvement of the distal left PCA branches
MRI/MRA (3 month follow up): Interval resolution of previously seen predominantly white matter T2 FLAIR
hyperintensity in the parietal and occipital lobes involving subcortical and deep white matter. Central pontine T2
FLAIR hyperintensity persists and is not substantially changed in the interval. There also has been interval resolution of the previously seen irregularity involving the distal left MCA, left ACA, right PCA, and left PCA
CT: Acute parenchymal hemorrhage centered in the left frontal lobe measuring 2.8 £ 2.4 £ 2.3cm with adjacent
vasogenic edema. There is a large volume subarachnoid hemorrhage that emanates from this position and is likely
a direct extension from the parenchymal hemorrhage. It is also present in the interpeduncular cistern, ambient cistern, and extends to the left sylvian fissure. There is additional subarachnoid hemorrhage present in the left frontoparietal convexity and right temporal sulci.
CTA: Left MCA M2 distribution multivessel long segment high-grade stenosis affecting essentially all of the M2
segment branches. High-grade stenosis extends into the M3 segment and M4 segment of multiple of these branches
as well. This is in the region of the large subarachnoid hemorrhage. Low-attenuation in the left thalamus and
medial left basal ganglia is nonspecific but suspicious for acute ischemic change.
DSA: Multifocal caliber irregularities in the left MCA, affecting the larger proximal branches as well as the smaller
distal vessels.
CTA (3 month follow up): Interval significant improvement of previously seen stenosis involving the left M2, M3,
and M4 segments
CTA (1): Approximately 50% stenosis of the proximal portion of the left internal carotid artery. Multifocal areas of
moderate to marked stenosis of nearly all intracranial vessels. Vertebrobasilar junction and the basilar artery demonstrate multifocal areas of stenosis and luminal irregularity but is patent throughout its course. There is an luminal
irregularity near the tip of the basal artery at the takeoff of the bilateral posterior cerebral arteries.
CTA (2): Moderate irregular stenosis of the distal left internal carotid artery and proximal portions of the left MCA
and ACA. Severe stenosis of the terminal right ICA and of the proximal right ACA and MCA. The more distal
right MCA and its branches are partially patent, improved from prior.
MRI: Large areas of restricted diffusion involving the R MCA, L parietal; also with FLAIR gyral swelling in the R
posterior cerebral cortex with minimal convexal SAH of the right parietal lobe
CTA: Diminutive L MCA (M1) branch with only minimal reconstitution of a few distal cortical branches. Paucity of
opacified intracranial arteries with focal narrowing. Occlusion of mid to distal right ACA A2 segment.
CTA: Unremarkable
MRI/MRA: Unremarkable
DSA: Unremarkable
CTA: Convexal SAH left superior parietal lobe, subtle multifocal stenosis of the bilateral ACA and MCA
MRI: Convexal SAH of left superior parietal lobe, small SDH of left parietal lobe
DSA: Mild left cervical ICA irregularity
CT/MRI/MRA (3 week follow up): CT head with residual left parietal SAH; MRI/MRA with residual SAH, small
SDH
CTA: L inferior M2 occlusion
DSA: L inferior division M2 occlusion s/p mechanical thrombectomy with TICI3 reperfusion. Diffuse vasculopathy
of the M2 and M3 divisions of bilateral MCA, left pericallosal artery
MRI: Mixed signal intensity areas corresponding to the region of hypodensity and sulcal effacement in the L frontal
lobe and insula are consistent with recent infarction. Areas of restricted diffusion in other portions of L frontal,
parietal, and occipital lobes, L posterior limb of internal capsule extending to brainstem and punctate area in the R
frontal lobe. Moderate bilateral confluent FLAIR hyperintensities are typical of small vessel disease.
CTA (1): Progressive moderate/severe narrowing involving the proximal/mid M1 segment of the L MCA and distal
M1 of R MCA. Multifocal severe luminal narrowing of M2 branches of bilateral MCA. Moderate stenosis of R A1
and R P1
MRI/MRA: 3cm hemorrhage in the L occipital lobe. Narrowing of the precavernous L ICA. Slightly decreased caliber of the M1 segment of the L MCA is seen, however no significant focal stenosis is seen. The M1 segment of the
R MCA is unremarkable. ACA and PCA are unremarkable.

Patient 2

Patient 3

Patient 4
Patient 5

Patient 6

Patient 7

Patient 8

(Continued)
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Table 3 (Continued)
Patient

Imaging

Patient 9

CTA (2): Stable IPH in the L occipital lobe, more extensive than better demarcated hypodensities in the bilateral
parietal and occipital lobes representing recent ischemic infarcts; multifocal mod/severe involving bilateral M1/
M2 segments, bilateral A1 segments, R>L, bilateral A2, bilateral PCA worsened from prior
DSA: Diffuse multifocal narrowings of the intracranial circulation involving the MCA, ACA, and PCA as well as
the PICA/AICA. There was moderate improvement after injection of small dose milrinone and verapamil.
CTA: Diffuse vasospasm
MRI/MRA: Acute ischemic bilateral occipital strokes; Diffuse vasospasm
DSA: Subtle diffuse irregularity of the distal MCA territories bilaterally. Attenuated posterior cerebral artery parietal
occipital territories.
CTA: Diffuse intracranial vascular abnormalities concerning for vasospasm or vasculitis. No large territory infarct
on CT perfusion.

Patient 10

which exacerbate the effects of cerebral vasoconstriction is
unknown.
Outcomes were poorer in our series than previously
described.23 Of our cohort of 10 patients, two patients
died, ﬁve required the ICU for respiratory support, and
one remained on a ventilator at the time of publication.
Both patients who died had diffuse multifocal intracranial
vasospasm with ischemic strokes on initial imaging, one
of whom died despite resolving vasospasm on repeat
imaging. Poorer course cannot be attributed solely to the
systemic complications of COVID-19 as one of the deaths
occurred in a patient without respiratory complications.

Fig. 1. Left occipital intraparenchymal hemorrhage measuring
2.8 £ 1.8 £ 2.1 cm with mild surrounding vasogenic edema and resulting
in mass effect effacing the overlying sulci on head CT (1a) and on SWI
sequence MRI (1b). Acute ischemic strokes and petechial hemorrhage involving the left frontal, insular, parietal, and occipital lobes (2a, 2b).

An important confounder to the clinical outcome of our
patient cohort is glucocorticoid exposure which is associated with clinical, radiographic, and angiographic worsening as well as poor outcome.24 Three patients were
administered IV dexamethasone for severe COVID Pneumonia/ARDS with one still intubated in the ICU, one just
recently extubated and with improving clinical course,
and the last was discharged home with an mRS of 0. One

Fig. 2. Hyperintensities involving the bilateral temporal, parietal, and
occipital subcortical white matter and pons without restricted diffusion or
enhancement on FLAIR sequence MRI (3a, 3b). Acute parenchymal hemorrhage of the left frontal lobe measuring 2.8 £ 2.4 £ 2.3 cm with adjacent
vasogenic edema. There is a large volume subarachnoid hemorrhage that is
likely extension from the intraparenchymal hemorrhage and is present in the
interpeduncular cistern, ambient cistern, left sylvian ﬁssure, left frontoparietal convexity, and right temporal sulci (4a, 4b).

REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME IN PATIENTS WITH CORONAVIRUS DISEASE

Fig. 3. There is moderate-severe narrowing of the A1 segments, moderate
narrowing of the left A2 and A3 segments, multifocal eccentric and concentric narrowings at the pericallosal and callosomarginal arteries, severe narrowing of the right temporal branch of the M1, moderate-severe narrowing
of the left M1, severe multifocal narrowing of the left M2 and distal M4 segments, and multifocal narrowing of the bilateral PCA, PICA, AICA, and
SCA (5a, 5b, 5c, 5d).

patient was taking PO prednisone for COVID Pneumonia
as an outpatient before her hospitalization for RCVS and
ultimately died in the ICU. The last patient was administered IV methylprednisolone for empiric treatment of
inﬂammatory vasculopathy with worsening clinical status,
interval strokes and vasogenic edema, worsening vasoconstriction on interval angiographic imaging, and death.
Poorer course and outcome of RCVS cannot be attributed
solely to glucocorticoid exposure as four out of ﬁve patients
also were critically ill with COVID-19 infection.
There are several limitations of our study, most notably
the small number of cases, uncertainty of diagnosis in
some, and the lack of interval follow-up imaging and
functional outcomes in most patients. Diagnosing RCVS
has a high speciﬁcity of 99% and a high sensitivity of 90%
when the RCVS2 score is greater than 525; however, only
ﬁve of the ten patients met this criteria. The remaining
ﬁve patients with RCVS2 scores <5 did not experience a
thunderclap headache. While uncommon, a literature
review identiﬁed 87 patients with RCVS who did not
have a thunderclap headache and instead experienced an
atypical, new headache, focal neurological deﬁcits, seizures, or encephalopathy.26 Furthermore, four of the ﬁve
patients in our study with RCVS2 scores <5 were either
obtunded or aphasic and all required intubation with ICU
level care; thus, a clinical history could not be obtained.
The remaining patient had an equivocal RCVS2 score
because her new, intractable headache on admission was
attributed to the severity of her COVID Pneumonia and
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the temporal course of her headache was not clariﬁed.
With this said, it is important to consider alternative
inﬂammatory vasculopathies when the diagnosis is
unclear, for which CSF studies could be helpful. We noted
in our group of ten patients that only two patients underwent a lumbar puncture with resulting CSF studies that
were non-inﬂammatory.
Despite these limitations, we believe it is important to
report these cases given the plausibility of a pathophysiologic basis for viral provocation of RCVS. Our limited
study has shown that COVID patients with RCVS have
worse outcomes than previously reported cohorts of
patients with RCVS, thus making it an important diagnosis to pursue and aggressively manage.
This multicenter case series may suggest a possible
association between RCVS and COVID-19 however the
exact relationship remains unclear. A larger cohort study
is needed in order to validate a causal relationship, establish risk factors, assess disease severity and neurologic
involvement, and ultimately aid in prognostication and in
treatment.

Declaration of Competing Interest
None.

References
1. Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 2007;146:34.
2. Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, et al.
Acute cerebrovascular disease following COVID-19: a
single center, retrospective, observational study. SSRN
Electron J [Internet] 2020. [cited 2020 Jun 8]; Available
from https://www.ssrn.com/abstract=3550025.
3. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in
COVID-19: a systematic review and meta-analysis. Int J
Stroke 2021;16:137-149.
4. Siow I, Lee KS, Zhang JJY, Saffari SE, Ng A, Young B.
Stroke as a neurological complication of COVID-19: a systematic review and meta-analysis of incidence, outcomes
and predictors. J Stroke Cerebrovasc Dis 2021;30:105549.
5. Yamakawa M, Kuno T, Mikami T, Takagi H, Gronseth G.
clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc
Dis 2020;29:105288.
6. Melmed KR, Cao M, Dogra S, Zhang R, Yaghi S, Lewis A,
et al. Risk factors for intracerebral hemorrhage in patients
with COVID-19. J Thromb Thrombolysis [Internet] 2020.
[cited 2020 Oct 8]; Available from: http://link.springer.
com/10.1007/s11239-020-02288-0.
7. Nwajei F, Anand P, Abdalkader M, Arasa VCA, Aparicio
HJ, Behbahani S, et al. Cerebral venous sinus thromboses
in patients with SARS-CoV-2 infection: three cases and a
review of the literature. J Stroke Cerebrovasc Dis
2020:105412.
8. Abdalkader M, Shaikh SP, Siegler JE, Cervantes-Arslanian
AM, Tiu C, Radu RA, et al. Cerebral venous sinus thrombosis in COVID-19 patients: a multicenter study and
review of literature. J Stroke Cerebrovasc Dis 2021:105733.

K. ARANDELA ET AL.

10
9. Anand P, Lau KHV, Chung DY, Virmani D, CervantesArslanian AM, Mian A, et al. Posterior reversible encephalopathy syndrome in patients with coronavirus disease
2019: two cases and a review of the literature. J Stroke
Cerebrovasc Dis 2020:105212.
10. Divani AA, Andalib S, Di Napoli M, Lattanzi S, Hussain
MS, Biller J, et al. Coronavirus disease 2019 and stroke:
clinical manifestations and pathophysiological insights. J
Stroke Cerebrovasc Dis 2020;29:104941.
11. Hess DC, Eldahshan W, Rutkowski E. COVID-19-related
stroke. Transl Stroke Res 2020;11:322-325.
12. Pugin D, Vargas M-I, Thieffry C, Schibler M, Grosgurin
O, Pugin J, et al. COVID-19-related encephalopathy
responsive to high doses glucocorticoids. Neurology
2020. 10.1212/WNL.0000000000010354.
13. Kirschenbaum D, Imbach LL, Rushing EJ, Frauenknecht
KBM, Gascho D, Ineichen BV, et al. Intracerebral endotheliitis and microbleeds are neuropathological features of
COVID-19. Neuropathol Appl Neurobiol 2020. nan.12677.
14. Mansoor T, Alsarah AA, Mousavi H, Khader Eliyas J,
Girotra T, Hussein O. COVID-19 associated reversible
cerebral vasoconstriction syndrome successfully treated
with nimodipine and aspirin. J Stroke Cerebrovasc Dis
2021;30:105822.
15. Dakay K, Kaur G, Gulko E, Santarelli J, Bowers C, Mayer
SA, et al. Reversible cerebral vasoconstriction syndrome
and dissection in the setting of COVID-19 infection. J
Stroke Cerebrovasc Dis 2020;29:105011.
16. Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol 2012;11:906-917.
17. Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D.
Reversible cerebral vasoconstriction SYNDROME, part 1:
epidemiology, pathogenesis, and clinical course. Am J Neuroradiol 2015;36(8):1392-1399. https://doi.org/10.3174/
ajnr.a4214.
18. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic

19.

20.

21.

22.
23.

24.

25.

26.

manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol [Internet]
2020. [cited 2020 Aug 5]; Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/
2766766.
Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al.
Nervous system involvement after infection with
COVID-19 and other coronaviruses. Brain Behav Immun
2020;87:18-22.
Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral
blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) [Internet]. Hematology 2020
Feb. Available from: http://medrxiv.org/lookup/doi/
10.1101/2020.02.10.20021832.
Ducros A, Boukobza M, Porcher R, Sarov M, Valade D,
Bousser M-G. The clinical and radiological spectrum of
reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007;130:3091-3101.
Singhal AB. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol 2011;68:1005.
Boitet R, de Gaalon S, Duﬂos C, Marin G, Mawet J, Burcin
C, et al. Long-term outcomes after reversible cerebral
vasoconstriction syndrome.:4.
Singhal AB, Topcuoglu MA. Glucocorticoid-associated
worsening in reversible cerebral vasoconstriction syndrome. Neurology 2017 Jan 17;88(3):228-236. doi:
10.1212/WNL.0000000000003510. Epub 2016 Dec 9.
PMID: 27940651; PMCID: PMC5272793.
Rocha EA, Topcuoglu MA, Silva GS, Singhal AB. RCVS 2
score and diagnostic approach for reversible cerebral
vasoconstriction syndrome. Neurology 2019;92:e639e647.
Wolff V, Ducros A. Reversible cerebral vasoconstriction
syndrome without typical thunderclap headache. Headache
2016;56(4):674-687.
https://doi.org/10.1111/
head.12794.

